Compositions for the treatment of sarcopenia or disuse atrophy
AssigneesAssociation Institut De Myologie, Inserm (Institut National De La Sante Et De La Recherche Medicale), Sorbonne Universite
InventorsFrance Pietri-Rouxel, Sestina Falcone
Life of this patent
Estimating the term…
Abstract
The present invention relates to a substance that activates the GDF5 pathway, for use in a method for the treatment of age-related sarcopenia or disuse atrophy.
Claims14
A method for the treatment or prevention of sarcopenia or disuse atrophy in a subject, the method comprising administering to the subject a substance selected from the group consisting of a synthetic or recombinant GDF5 protein, a GDF5 peptide and a vector encoding GDF5.
A method for treating or preventing muscle weakness in Duchenne muscular dystrophy or amyotrophic lateral sclerosis in a subject, the method comprising administering to the subject a substance selected from the group consisting of a synthetic or recombinant GDF5 protein, a GDF5 peptide and a vector encoding GDF5, alone or in combination with a treatment of Duchenne muscular dystrophy or amyotrophic lateral sclerosis.
Dependencies are inferred from the claim text.